# A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07043400** · PHASE3 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 351 (estimated)

## Conditions studied

- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Subcutaneous Tislelizumab
- **DRUG:** Intravenous Tislelizumab
- **DRUG:** Cisplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07043400
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2027-10-30
- **Final completion:** 2028-04-22
- **Target enrollment:** 351 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043400, "A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT07043400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*